Aurora Investment Counsel Has Lifted Henry Schein (HSIC) Holding By $420,291; CANNABIS SCIENCE (CBIS) Shorts Lowered By 5.95%

Thursday, 31 May 2018

Aurora Investment Counsel Has Lifted Henry Schein (HSIC) Holding By $420,291; CANNABIS SCIENCE (CBIS) Shorts Lowered By 5.95%

Cannabis Science, Inc. (OTCMKTS:CBIS) Logo

CANNABIS SCIENCE INC (OTCMKTS:CBIS) had a decrease of 5.95% in short interest. CBIS’s SI was 210,200 shares in May as released by FINRA. Its down 5.95% from 223,500 shares previously. The SI to CANNABIS SCIENCE INC’s float is 0.01%. The stock 1.38% or $0 during the last trading session, reaching $0.06. It is down 0.00% since May 31, 2017 and is . It has underperformed by 12.57% the S&P500.

Aurora Investment Counsel increased Henry Schein Inc. (HSIC) stake by 27.74% reported in 2018Q1 SEC filing. Aurora Investment Counsel acquired 6,273 shares as Henry Schein Inc. (HSIC)’s stock rose 4.05%. The Aurora Investment Counsel holds 28,884 shares with $1.94M value, up from 22,611 last quarter. Henry Schein Inc. now has $11.03B valuation. The stock increased 2.29% or $1.6 during the last trading session, reaching $71.6. About 1.67M shares traded or 0.61% up from the average. Henry Schein, Inc. (NASDAQ:HSIC) has declined 23.14% since May 31, 2017 and is downtrending. It has underperformed by 35.71% the S&P500.

Aurora Investment Counsel decreased Bofi Holding Inc. (NASDAQ:BOFI) stake by 43,079 shares to 50,858 valued at $2.06M in 2018Q1. It also reduced Lasalle Hotel Properties (NYSE:LHO) stake by 26,758 shares and now owns 32,108 shares. Akamai Technologies Inc. (NASDAQ:AKAM) was reduced too.

Investors sentiment increased to 0.86 in 2018 Q1. Its up 0.03, from 0.83 in 2017Q4. It improved, as 55 investors sold HSIC shares while 169 reduced holdings. 61 funds opened positions while 132 raised stakes. 158.34 million shares or 8.33% more from 146.17 million shares in 2017Q4 were reported. Ami Asset Mngmt Corporation stated it has 423,433 shares. Peloton Wealth Strategists invested in 20,650 shares. Canandaigua Financial Bank Trust Co holds 0.03% or 3,941 shares in its portfolio. Lifeplan Fincl Gru stated it has 99 shares. Wilbanks Smith & Thomas Asset Mngmt Ltd Liability Company stated it has 0.02% in Henry Schein, Inc. (NASDAQ:HSIC). Mitsubishi Ufj Tru And Bk Corp holds 350,716 shares. Oppenheimer Asset Mgmt reported 0.1% in Henry Schein, Inc. (NASDAQ:HSIC). Gotham Asset Mgmt Lc reported 0.01% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC). 46,779 were accumulated by Neville Rodie Shaw Inc. 116,674 were reported by Quantum Mngmt Ltd Llc Nj. Moreover, British Columbia Investment Mngmt Corp has 0.13% invested in Henry Schein, Inc. (NASDAQ:HSIC). Teacher Retirement Systems Of Texas has 0.02% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 34,726 shares. 3,720 were reported by Sentry Corp. Bancorporation Of Montreal Can owns 403,071 shares. Zuckerman Gru Ltd Llc reported 101,045 shares.

More notable recent Henry Schein, Inc. (NASDAQ:HSIC) news were published by: Prnewswire.com which released: “Stanley Bergman Addresses Western University of Health Sciences Dental, Pharmacy, and Veterinary Graduates” on May 29, 2018, also Seekingalpha.com with their article: “Tracking Al Gore’s Generation Investment Management Portfolio – Q1 2018 Update” published on May 26, 2018, Seekingalpha.com published: “Henry Schein (HSIC) Q1 2018 Results – Earnings Call Transcript” on May 08, 2018. More interesting news about Henry Schein, Inc. (NASDAQ:HSIC) were released by: Prnewswire.com and their article: “Henry Schein To Present At Three Investor Conferences In June” published on May 23, 2018 as well as Prnewswire.com‘s news article titled: “Henry Schein Rises To #238 On The FORTUNE 500®” with publication date: May 21, 2018.

Among 23 analysts covering Henry Schein Inc. (NASDAQ:HSIC), 12 have Buy rating, 1 Sell and 10 Hold. Therefore 52% are positive. Henry Schein Inc. had 56 analyst reports since July 31, 2015 according to SRatingsIntel. As per Wednesday, April 4, the company rating was upgraded by Leerink Swann. The firm has “Hold” rating by Leerink Swann given on Tuesday, February 13. The rating was upgraded by PiperJaffray on Friday, September 15 to “Overweight”. The firm has “Buy” rating by Craig Hallum given on Tuesday, November 7. The rating was maintained by Leerink Swann on Wednesday, February 21 with “Market Perform”. The rating was initiated by Deutsche Bank with “Buy” on Friday, December 8. The stock of Henry Schein, Inc. (NASDAQ:HSIC) has “Buy” rating given on Thursday, October 19 by Robert W. Baird. The rating was maintained by Barrington Research on Wednesday, February 22 with “Outperform”. Jefferies maintained Henry Schein, Inc. (NASDAQ:HSIC) on Thursday, July 20 with “Hold” rating. The firm has “Hold” rating given on Tuesday, November 28 by Credit Suisse.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $153.11 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.

Another recent and important Cannabis Science, Inc. (OTCMKTS:CBIS) news was published by Investorplace.com which published an article titled: “30 Marijuana Stocks to Buy as the Future Turns Green” on May 14, 2018.

Henry Schein, Inc. (NASDAQ:HSIC) Institutional Positions Chart